Lisinopril ace
Pro Research Analysisby 
Searched over 200M research papers for "lisinopril ace"
Lisinopril and Angiotensin-Converting Enzyme (ACE)
Introduction to Lisinopril and ACE Inhibition
Lisinopril is a widely used angiotensin-converting enzyme (ACE) inhibitor, primarily prescribed for managing hypertension, heart failure, and certain kidney conditions. By inhibiting ACE, lisinopril reduces the production of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure and alleviating strain on the heart.
Lisinopril and ACE2 Expression
Recent studies have explored the impact of lisinopril on ACE2, the receptor for SARS-CoV-2. Research on healthy mice demonstrated that oral administration of lisinopril significantly increased ACE2 protein levels across various tissues, including the small intestine, lung, kidney, and brain . This elevation persisted even after discontinuation of the drug, suggesting a lasting effect. Interestingly, the combination of lisinopril with losartan, an angiotensin receptor blocker, prevented this increase in ACE2 levels .
Genetic Polymorphisms and Renal Disease Progression
The EURODIAB Controlled Trial of Lisinopril in IDDM patients investigated the influence of ACE gene polymorphisms on renal disease progression. The study found that patients with the II genotype exhibited the fastest progression of albumin excretion rate (AER) on placebo but responded most favorably to lisinopril treatment, showing a significant reduction in AER . This suggests that genetic factors may modulate the therapeutic efficacy of lisinopril in diabetic nephropathy.
Lisinopril in Hypoxic Pulmonary Vasoconstriction
Lisinopril has also been shown to attenuate acute hypoxic pulmonary vasoconstriction (HPV) in humans. In a randomized, double-blind, placebo-controlled study, lisinopril significantly blunted the increase in mean pulmonary artery pressure and total pulmonary vascular resistance induced by hypoxemia, without affecting systemic hemodynamics . This indicates a potential role for ACE inhibition in managing hypoxemic pulmonary hypertension.
Impact on Diabetic Nephropathy
Several studies have highlighted the benefits of lisinopril in diabetic nephropathy. In normotensive patients with insulin-dependent diabetes mellitus (IDDM) and varying degrees of albuminuria, lisinopril significantly slowed the progression of renal disease, particularly in those with microalbuminuria . Another study comparing lisinopril with atenolol in hypertensive non-insulin-dependent diabetes mellitus (NIDDM) patients found that both drugs effectively reduced the decline in kidney function, but lisinopril had a more pronounced effect on reducing urinary albumin excretion .
Pharmacokinetics and Domain Selectivity
Lisinopril-tryptophan (LisW-S), a novel C-domain selective ACE inhibitor, has been developed to improve the side effect profile of traditional ACE inhibitors. Pharmacokinetic studies in rats showed that LisW-S has a low oral bioavailability but provides a basis for understanding its absorption and potential clinical applications . Structural studies have further elucidated the binding specificity of lisinopril in the N- and C-domains of human somatic ACE, aiding in the design of more selective inhibitors .
Cardiovascular Benefits in Myocardial Infarction
Lisinopril has demonstrated significant benefits in the early management of acute myocardial infarction. The GISSI-3 trial showed that early administration of lisinopril reduced mortality and cardiovascular morbidity, with benefits persisting even after discontinuation of the drug . This underscores the importance of ACE inhibitors in the acute phase of myocardial infarction.
Dose-Response in Chronic Heart Failure
The ATLAS study compared the effects of low and high doses of lisinopril in patients with chronic heart failure. High doses were associated with a significant reduction in hospitalizations for heart failure and a lower risk of death or hospitalization for any reason, although the difference in mortality alone was not statistically significant . This suggests that higher doses of lisinopril may offer greater clinical benefits in heart failure management.
Conclusion
Lisinopril, as an ACE inhibitor, plays a crucial role in managing various cardiovascular and renal conditions. Its effects on ACE2 expression, genetic polymorphisms, hypoxic pulmonary vasoconstriction, and diabetic nephropathy highlight its multifaceted therapeutic potential. Additionally, its benefits in myocardial infarction and chronic heart failure further establish lisinopril as a cornerstone in cardiovascular therapy. Future research may continue to optimize its use and explore novel selective inhibitors to enhance patient outcomes.
Sources and full results
Most relevant research papers on this topic
Oral Lisinopril Raises Tissue Levels of ACE2, the SARS-CoV-2 Receptor, in Healthy Male and Female Mice
Oral lisinopril increases ACE2 in tissues relevant to COVID-19 transmission and pathogenesis, but the addition of losartan prevents these increases in ACE2 levels.
Lisinopril attenuates acute hypoxic pulmonary vasoconstriction in humans.
Lisinopril significantly reduces the pulmonary pressor response to hypoxemia without decreasing baseline mean arterial pressure or total pulmonary vascular resistance, suggesting it may be a useful adjunctive treatment for hypoxemic pulmonary hypertension.
Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor.
Lisinopril-tryptophan, a novel C-domain ACE inhibitor, shows high selectivity and a 5.4% oral bioavailability, with potential clinical applications in treating hypertension.
DOI